What is the prevalence of fear of cancer recurrence in cancer survivors and patients? A systematic review and individual participant data meta-analysis

Yvonne L. Luigjes-Huizer*, Nina M. Tauber, Gerry Humphris, Nadine A. Kasparian, Wendy W.T. Lam, Sophie Lebel, Sébastien Simard, Allan Ben Smith, Robert Zachariae, Yati Afiyanti, Katy J.L. Bell, José A.E. Custers, Niek J. de Wit, Peter L. Fisher, Jacqueline Galica, Sheila N. Garland, Charles W. Helsper, Mette M. Jeppesen, Jianlin Liu, Roxana MititeluEvelyn M. Monninkhof, Lahiru Russell, Josée Savard, Anne E.M. Speckens, Sanne J. van Helmondt, Sina Vatandoust, Nicholas Zdenkowski, Marije L. van der Lee


Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

35 Downloads (Pure)


Objective: Care for fear of cancer recurrence (FCR) is considered the most common unmet need among cancer survivors. Yet the prevalence of FCR and predisposing factors remain inconclusive. To support targeted care, we provide a comprehensive overview of the prevalence and severity of FCR among cancer survivors and patients, as measured using the short form of the validated Fear of Cancer Recurrence Inventory (FCRI-SF). We also report on associations between FCR and clinical and demographic characteristics. Methods: This is a systematic review and individual participant data (IPD) meta-analysis on the prevalence of FCR. In the review, we included all studies that used the FCRI-SF with adult (≥18 years) cancer survivors and patients. Date of search: 7 February 2020. Risk of bias was assessed using the Joanna Briggs Institute critical appraisal tool. Results: IPD were requested from 87 unique studies and provided for 46 studies comprising 11,226 participants from 13 countries. 9311 respondents were included for the main analyses. On the FCRI-SF (range 0–36), 58.8% of respondents scored ≥13, 45.1% scored ≥16 and 19.2% scored ≥22. FCR decreased with age and women reported more FCR than men. FCR was found across cancer types and continents and for all time periods since cancer diagnosis. Conclusions: FCR affects a considerable number of cancer survivors and patients. It is therefore important that healthcare providers discuss this issue with their patients and provide treatment when needed. Further research is needed to investigate how best to prevent and treat FCR and to identify other factors associated with FCR. The protocol was prospectively registered (PROSPERO CRD42020142185).

Udgave nummer6
Sider (fra-til)879-892
StatusUdgivet - jun. 2022

Bibliografisk note

Funding Information:
Buffart, L.M. provided example formats for the data sharing agreement and access and publication policy. Afiyanti, Y., Ahn, Y., Bell, K.J.L., Cilessen, L., Corter, A.L., Custers, J.A.E., Dirkse, D., Dixon, C.L., Eyrenci, A., Fisher, P.L., Galica, J., Garland, S.N., Hebert, J., Jakobsen, I., Jeppesen, M.M., Johns, S.A., Jun, S. Kang, D.W., Lam, W.W.T., Lebel, S., Luigjes‐Huizer, Y.L., Maheu, C., Liu, J., Mititelu, R., Murphy, M.J., Otto, A.K., Russell, L., Savard, J., Simard, S., Speckens, A., Sukyati, I., Tauber, N.M., van der Gucht, K., van Helmondt, S.J., Vatandoust, S., Wijayanti, T. and Zdenkowski, N. shared their data and contributed to the study concept, design, and conduct of the study that they were responsible for. Luigjes‐Huizer, Y.L., Helsper, C.W., van der Lee, M.L. and Monninkhof, E.M. drafted the manuscript. All authors critically reviewed the manuscript and approved the final version. This study was supported by the Dutch Cancer Society (KWF) grant number 10936. KWF is not involved in study design, collection, management, analysis and interpretation of data, writing of the report and decision to submit the report for publication, nor does it have authority over the publications.


Dyk ned i forskningsemnerne om 'What is the prevalence of fear of cancer recurrence in cancer survivors and patients? A systematic review and individual participant data meta-analysis'. Sammen danner de et unikt fingeraftryk.